Cargando…
Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells
BACKGROUND: Mesothelin is a 40-kDa glycoprotein that is highly overexpressed in various types of cancers, however molecular mechanism of mesothelin has not been well-known. Amatuximab is a chimeric monoclonal IgG1/k antibody targeting mesothelin. We recently demonstrated that the combine therapy of...
Autores principales: | Matsuzawa, Fumihiko, Kamachi, Hirofumi, Mizukami, Tatsuzo, Einama, Takahiro, Kawamata, Futoshi, Fujii, Yuki, Fukai, Moto, Kobayashi, Nozomi, Hatanaka, Yutaka, Taketomi, Akinobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912898/ https://www.ncbi.nlm.nih.gov/pubmed/33637083 http://dx.doi.org/10.1186/s12885-020-07722-3 |
Ejemplares similares
-
The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model
por: Mizukami, Tatsuzo, et al.
Publicado: (2018) -
Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017) -
Amatuximab and novel agents targeting mesothelin for solid tumors
por: Baldo, Paolo, et al.
Publicado: (2017) -
Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms
por: EINAMA, TAKAHIRO, et al.
Publicado: (2015) -
Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
por: Einama, T, et al.
Publicado: (2012)